Xenetic Biosciences and VolitionRx have entered into a research and development collaboration to develop neutrophil extracellular traps (NETs)-targeted, adoptive cell therapies for the treatment of cancer.

Caris Life Sciences and Xencor have entered into a multi-year strategic option and license agreement to research, develop and commercialize XmAb bispecific antibodies directed against novel targets for the treatment of patients with cancer.

Ipsen and Marengo Therapeutics have entered into a strategic partnership to advance two of Marengo's preclinical STAR (Selective T Cell Activation Repertoire) platform-generated candidates into the clinic.